What is the current market size?

The Liquid Biopsy Technology market size reached USD 1.8 billion in 2023, driven by advancements in cancer diagnostics and early detection.

What is the expected growth rate?

The market is projected to grow at a CAGR of 12.4% from 2024 to 2032, reflecting rising demand for non-invasive diagnostic tools.

What are the key growth drivers?

Key drivers include increasing cancer incidence, technological innovations in biomarker detection, and growing adoption in personalized medicine.

What challenges does the market face?

Challenges include high costs of advanced testing, limited reimbursement policies, and variability in sample handling and analysis standards.

Which regions are leading the market?

North America dominates the market, followed by Europe, due to strong healthcare infrastructure and supportive regulatory frameworks.

Who are the top companies?

Leading companies include Guardant Health, Qiagen, Thermo Fisher Scientific, and Roche Diagnostics, focusing on R&D and strategic partnerships.

What future opportunities exist?

Expanding applications in non-oncology fields like infectious diseases and prenatal screening present significant growth opportunities.

How is technology shaping the future?

Next-generation sequencing (NGS) and AI-powered analytics are enhancing precision, enabling earlier and more accurate detection of biomarkers.

What is the regulatory landscape like?

Regulatory bodies like the FDA and EMA are streamlining approvals for liquid biopsy tests, ensuring standardization and improving patient access.

How will the market evolve post-pandemic?

The pandemic has accelerated digital health adoption, fostering growth in remote diagnostics and decentralized liquid biopsy testing solutions.

Liquid Biopsy Technology Market Comprehensive Report: 200+ Pages | 2026–2034

Liquid Biopsy Technology by Application (Blood Sample, Urine Sample, Other Bio Fluids), by Types (CTCs, ctDNA, Exosomes), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Liquid Biopsy Technology Market Size | CAGR 14.5 Forecast 2033

Liquid Biopsy Technology Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Liquid Biopsy Technology Market Overview

The Liquid Biopsy Technology market is a transformative segment in oncology and diagnostics, enabling non-invasive detection of biomarkers through blood or other biofluid samples. With growing emphasis on precision medicine and early cancer detection, this market is pivotal in reshaping disease management strategies. The global Liquid Biopsy Technology market size is projected to reach USD 3.2 billion by 2033, expanding at a compound annual growth rate (CAGR) of 13.5% during the forecast period (2026–2033). This growth outlook underscores a strategic shift toward minimally invasive diagnostics, driven by advancements in next-generation sequencing (NGS) and rising demand for personalized healthcare solutions.

Loading chart…

The market forecast highlights North America as the largest contributor due to robust R&D investments and a well-established oncology infrastructure, while Asia-Pacific is the fastest-growing region, fueled by rising healthcare expenditures and expanding molecular diagnostics adoption. Key drivers include regulatory approvals for ctDNA-based tests, integration of AI for biomarker analysis, and partnerships between biotech firms to enhance assay accuracy. However, challenges such as high costs and reimbursement limitations persist. Strategic innovations in circulating tumor DNA (ctDNA) and microRNA detection are poised to unlock new opportunities, solidifying the Liquid Biopsy Technology market as a cornerstone of modern diagnostic pathology.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	6.20 billion
Growth rate	CAGR of 14.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Exact Sciences; Guardant Health; Natera; Bio-Techne; LabCorp; Endress+Hauser; MDxHealth; MutantDx; Thermo Fisher Scientific; Norgen Biotek; Nucleix; OraSure Technologies; Qiagen; Bio-Rad Laboratories; Biocartis; NeoGenomics; Sysmex Inostics; Menarini Silicon Biosystems; Biocept; ANGLE plc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The non-invasive nature of Liquid Biopsy Technology is accelerating adoption in oncology, enabling real-time monitoring of treatment efficacy and early detection of cancer recurrence, which aligns with the global push for personalized medicine.

Advancements in next-generation sequencing (NGS) and artificial intelligence (AI) are enhancing the accuracy of circulating tumor DNA (ctDNA) analysis, expanding the Liquid Biopsy Technology market size and improving diagnostic confidence among clinicians.

Restraints2 items

High costs of advanced diagnostic equipment and specialized laboratory infrastructure limit accessibility, particularly in emerging markets with underfunded healthcare systems.

Regulatory fragmentation across regions creates delays in approval processes, hindering rapid scaling of Liquid Biopsy Technology innovations and deterring investment in R&D.

Opportunities2 items

The expanding application of liquid biopsies beyond oncology—such as in transplant monitoring and infectious disease diagnostics—presents untapped revenue streams for market players.

Strategic collaborations between biotech firms and payers to establish cost-effective reimbursement models are expected to drive the Liquid Biopsy Technology market growth forecast in high-potential regions like Asia-Pacific.

Challenges2 items

The lack of standardized protocols for sample collection, processing, and data interpretation creates variability in diagnostic outcomes, eroding trust in liquid biopsy results.

Intense competition from established players and disruptive startups is compressing profit margins, forcing companies to balance innovation with cost optimization.

Market Segmentation

Loading chart…

Under Liquid Biopsy Technology segmentation, the Application category is a critical driver of market dynamics. The primary subsegments include Cancer Diagnosis and Treatment Monitoring. Cancer Diagnosis dominates the market due to its role in early detection, mutational profiling, and non-invasive identification of tumor-specific biomarkers, accounting for ~65% of total application value. Treatment Monitoring follows, leveraging real-time tracking of therapy efficacy and resistance patterns to inform personalized oncology strategies. These applications collectively expand the market size by addressing unmet clinical needs, with Treatment Monitoring expected to grow faster due to rising demand for longitudinal patient data in precision medicine.

The Types segment within Liquid Biopsy Technology segmentation is defined by Circulating Tumor DNA (ctDNA) and Exosome-based Biopsy. Circulating Tumor DNA constitutes the largest share (~70%) due to its maturity in detecting genetic mutations via blood samples, supporting oncology diagnostics and drug development. Exosome-based Biopsy, though smaller, is the fastest-growing type, driven by advancements in exosome isolation and RNA/protein biomarker discovery. This subtype enhances the market’s diversity by enabling multi-omics analysis, catering to rare cancers and liquid tumor profiling. The typological split underscores technological innovation trajectories, with ctDNA anchoring current market value while exosomal approaches signal future growth potential.

Liquid Biopsy Technology Segmentation Breakdown8 items

Application

Blood Sample

Urine Sample

Other Bio Fluids

Types

CTCs

ctDNA

Exosomes

Regional Insights

Loading chart…

North America dominates the Liquid Biopsy Technology market, accounting for ~40% of the global share. The region’s growth is driven by advanced healthcare infrastructure, robust R&D investments, and favorable regulatory policies. High cancer prevalence and strong adoption of precision medicine further accelerate demand. The U.S. and Canada lead in ecosystem maturity, with strategic partnerships between biotech firms and academic institutions.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR exceeding 12% during the forecast period. Key drivers include rising cancer incidence, increasing healthcare expenditures, and government initiatives to modernize diagnostic capabilities. Countries like China and India are prioritizing liquid biopsy adoption to address oncology care gaps, while Japan’s aging population fuels demand for non-invasive testing.

Europe holds ~25% of the market, supported by stringent healthcare policies, cross-border collaborations, and a well-established biotechnology ecosystem. Germany, France, and the U.K. are pivotal in driving innovation, while the EU’s Horizon 2020 funding accelerates diagnostic advancements. Demographic shifts, including aging populations, also bolster regional demand.

Regional Growth Drivers2 items

Latin America: Emerging healthcare infrastructure and growing partnerships with global biotech firms are fostering adoption.

Middle East & Africa: Strategic investments in precision medicine and rising awareness of early cancer detection are unlocking growth potential.

The global Liquid Biopsy Technology market growth is increasingly shaped by regional disparities in infrastructure, policy, and demographics. Asia Pacific’s rapid adoption, North America’s leadership, and Europe’s regulatory support will define the regional forecast, while Latin America and the Middle East present untapped opportunities.

Competitive Landscape

The Liquid Biopsy Technology competitive landscape is moderately consolidated, with global players such as Thermo Fisher Scientific and Qiagen dominating key regions, while niche innovators like Natera and Bio-Rad Laboratories focus on specialized applications. Competitive differentiation is driven by proprietary technology platforms, regulatory approvals (e.g., CE-IVD, FDA clearance), and strategic partnerships with diagnostic labs. Pricing strategies vary by end-user segment, with academic institutions prioritizing cost efficiency and pharma companies investing in high-throughput solutions. Local/regional firms are gaining traction through localized manufacturing and compliance with emerging market regulations.

Key industry players leverage M&A, R&D investments, and distribution alliances to strengthen market position. Differentiation centers on technology (NGS vs qPCR), service models (turnkey vs component-based), and data analytics capabilities. A notable challenge is escalating compliance costs due to stringent regulatory requirements across geographies. Companies are also addressing supply chain risks by diversifying supplier networks and adopting hybrid manufacturing models to balance cost and quality.

Exact Sciences: regional expansion in oncology diagnostics

Guardant Health: innovation pipeline for rare mutation detection

Natera: OEM tie-ups for non-invasive prenatal testing

Thermo Fisher Scientific: vertical integration for reagent supply

Qiagen: premium pricing for automated sample prep systems

Bio-Rad Laboratories: localization of liquid biopsy kits in Asia-Pacific

Key Liquid Biopsy Technology Companies20 items

Exact Sciences

Guardant Health

Natera

Bio-Techne

LabCorp

Endress+Hauser

MDxHealth

MutantDx

Thermo Fisher Scientific

Norgen Biotek

Nucleix

OraSure Technologies

Qiagen

Bio-Rad Laboratories

Biocartis

NeoGenomics

Sysmex Inostics

Menarini Silicon Biosystems

Biocept

ANGLE plc

Market Ecosystem

The Liquid Biopsy Technology ecosystem spans upstream development of diagnostic tools, midstream integration into testing platforms, and downstream clinical deployment. Value creation hinges on cross-sector collaboration to advance non-invasive disease detection while ensuring regulatory and clinical validation. The system integrates specialized suppliers, technology innovators, and healthcare providers to deliver actionable biomarker insights.

Raw material/component suppliers — supply critical reagents, consumables, and lab equipment for sample processing

Technology providers — develop core assays, sequencing platforms, and AI-driven data analysis tools

System integrators — configure end-to-end solutions combining hardware, software, and workflow automation

Diagnostic laboratories — perform clinical testing and biomarker analysis for cancer and other diseases

Distributors/channel partners — facilitate access to emerging markets through localized sales and logistics

Regulatory bodies — establish approval pathways and standardize test validation protocols

Data analytics providers — enable biomarker interpretation through cloud-based bioinformatics platforms

Value flows are constrained by regulatory review timelines, dependency on high-quality sample collection methods, and interoperability requirements between diagnostic systems. Control points reside with technology providers holding proprietary IP and regulators shaping adoption criteria. Switching costs for end users remain elevated due to the need for specialized training and integrated data management ecosystems.

Recent Industry Insights

The Liquid Biopsy Technology industry trends have seen significant momentum over the past 18 months, driven by strategic collaborations and technological advancements. Key players have prioritized partnerships to enhance diagnostic accuracy, such as the alliance between Guardant Health and Quest Diagnostics to integrate liquid biopsy into clinical trial frameworks. Mergers & acquisitions have also surged, with Roche acquiring TAK Biotech to bolster its oncology diagnostics portfolio. Innovations in circulating tumor DNA (ctDNA) analysis led to the product/technology launches of next-generation sequencing (NGS)-based assays by companies like Grail and Personalis, expanding early cancer detection capabilities. Regulatory bodies have shown increased support, with the FDA granting breakthrough status to several liquid biopsy tests, streamlining their market entry. Consumer trends highlight a growing preference for non-invasive diagnostic options, particularly in oncology, while enterprise demand for precision medicine solutions continues to rise. The sector has also attracted substantial funding rounds, with startups like Freenome securing $150 million in Series C financing to advance AI-driven biomarker discovery. These developments underscore a maturing industry poised for accelerated adoption in 2024.

Analyst Overview

The Liquid Biopsy Technology market outlook remains highly promising, driven by rising demand for non-invasive diagnostic solutions in oncology. With advancements in next-generation sequencing and growing adoption for early cancer detection, the market exhibits strong attractiveness for investors. Competitive intensity is moderate, characterized by strategic collaborations between established players and emerging innovators, alongside a focus on expanding product portfolios. The long-term outlook is favorable, supported by increasing cancer prevalence and advancements in biomarker discovery, which are expected to fuel market growth beyond 2030. The innovation landscape is dynamic, with breakthroughs in AI-driven analytics and multi-omics integration enhancing diagnostic precision. However, a cautious demand–supply balance persists, as high R&D costs and regulatory complexities temper rapid scalability. Key risk factors include reimbursement challenges, stringent regulatory scrutiny, and competition from conventional biopsy methods. Stakeholders must prioritize cost optimization and clinical validation to sustain momentum in this evolving sector.

11 items

1. Executive Summary

2. Liquid Biopsy Technology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Liquid Biopsy Technology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Liquid Biopsy Technology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Blood Sample

6.1.2. Urine Sample

6.1.3. Other Bio Fluids

6.2. Global Liquid Biopsy Technology Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. CTCs

6.2.2. ctDNA

6.2.3. Exosomes

6.3. Global Liquid Biopsy Technology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Liquid Biopsy Technology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Liquid Biopsy Technology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Liquid Biopsy Technology Market Competition by Key Manufacturers

8.1. Global Liquid Biopsy Technology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Liquid Biopsy Technology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Exact Sciences

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Guardant Health

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Natera

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio-Techne

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. LabCorp

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Endress+Hauser

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. MDxHealth

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. MutantDx

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Thermo Fisher Scientific

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Norgen Biotek

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Nucleix

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. OraSure Technologies

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Qiagen

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Bio-Rad Laboratories

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Biocartis

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. NeoGenomics

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Sysmex Inostics

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Menarini Silicon Biosystems

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Biocept

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. ANGLE plc

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Liquid Biopsy Technology Market

Figure 4: Global Liquid Biopsy Technology Market: Drivers

Figure 5: Global Liquid Biopsy Technology Market: Challenges

Figure 6: Global Liquid Biopsy Technology Market: Trends

Figure 7: Global Liquid Biopsy Technology Market: Opportunity

Figure 8: Global Liquid Biopsy Technology Market: Restraint

Figure 9: Global Liquid Biopsy Technology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Liquid Biopsy Technology Market Value (USD Million) By Region

Figure 15: Global Liquid Biopsy Technology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Liquid Biopsy Technology Market Value (USD Million) By Region

Figure 23: Global Liquid Biopsy Technology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Liquid Biopsy Technology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Liquid Biopsy Technology Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Liquid Biopsy Technology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Liquid Biopsy Technology Market Value (USD Million) By Region

Table 10: Global Liquid Biopsy Technology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Liquid Biopsy Technology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Liquid Biopsy Technology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Liquid Biopsy Technology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Exact Sciences Basic Information And Sales Area

Table 31: Exact Sciences. Products Portfolio

Table 32: Guardant Health Basic Information And Sales Area

Table 33: Guardant Health. Products Portfolio

Table 34: Natera Basic Information And Sales Area

Table 35: Natera. Products Portfolio

Table 36: Bio-Techne Basic Information And Sales Area

Table 37: Bio-Techne. Products Portfolio

Table 38: LabCorp Basic Information And Sales Area

Table 39: LabCorp. Products Portfolio

Table 40: Endress+Hauser Basic Information And Sales Area

Table 41: Endress+Hauser. Products Portfolio

Table 42: MDxHealth Basic Information And Sales Area

Table 43: MDxHealth. Products Portfolio

Table 44: MutantDx Basic Information And Sales Area

Table 45: MutantDx. Products Portfolio

Table 46: Thermo Fisher Scientific Basic Information And Sales Area

Table 47: Thermo Fisher Scientific. Products Portfolio

Table 48: Norgen Biotek Basic Information And Sales Area

Table 49: Norgen Biotek. Products Portfolio

Table 50: Nucleix Basic Information And Sales Area

Table 51: Nucleix. Products Portfolio

Table 52: OraSure Technologies Basic Information And Sales Area

Table 53: OraSure Technologies. Products Portfolio

Table 54: Qiagen Basic Information And Sales Area

Table 55: Qiagen. Products Portfolio

Table 56: Bio-Rad Laboratories Basic Information And Sales Area

Table 57: Bio-Rad Laboratories. Products Portfolio

Table 58: Biocartis Basic Information And Sales Area

Table 59: Biocartis. Products Portfolio

Table 60: NeoGenomics Basic Information And Sales Area

Table 61: NeoGenomics. Products Portfolio

Table 62: Sysmex Inostics Basic Information And Sales Area

Table 63: Sysmex Inostics. Products Portfolio

Table 64: Menarini Silicon Biosystems Basic Information And Sales Area

Table 65: Menarini Silicon Biosystems. Products Portfolio

Table 66: Biocept Basic Information And Sales Area

Table 67: Biocept. Products Portfolio

Table 68: ANGLE plc Basic Information And Sales Area

Table 69: ANGLE plc. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Liquid Biopsy Technology Market Value (USD Million) By Region

Table 75: Global Liquid Biopsy Technology Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Liquid Biopsy Technology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	6.20 billion
Growth rate	CAGR of 14.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Exact Sciences; Guardant Health; Natera; Bio-Techne; LabCorp; Endress+Hauser; MDxHealth; MutantDx; Thermo Fisher Scientific; Norgen Biotek; Nucleix; OraSure Technologies; Qiagen; Bio-Rad Laboratories; Biocartis; NeoGenomics; Sysmex Inostics; Menarini Silicon Biosystems; Biocept; ANGLE plc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options